Literature DB >> 15588875

Post-operative treatment of malignant salivary gland tumours of the palate with iodine-125 brachytherapy.

Clare E Stannard1, Egbert Hering, Jan Hough, Ruth Knowles, Roger Munro, Jos Hille.   

Abstract

BACKGROUND AND
PURPOSE: Malignant minor salivary gland tumours are usually small and clinically indistinguishable from benign lesions. Surgery is the treatment of choice with post-operative radiotherapy for involved margins or unfavourable histology. We assessed the results of a series of such patients treated with iodine-125 brachytherapy in the form of a temporary applicator or implant. PATIENTS AND METHODS: There were nine patients with T1/T2 tumours of the hard and/or soft palate that had been excised. All had close or involved margins. Six were treated with a dental applicator alone, two with an applicator and additional I-125 seeds in tubes and one with an implant alone. The applicator consists of two layers of plastic made from a dental impression enclosing a predetermined number of I-125 seeds, 9-39, glued to one surface and a layer of ash metal to protect the tongue. It was inserted 1-3 months post-operatively and delivered 35-62 Gy, median 56 Gy, at 5-7 mm depth over 58-156 h, median 120 h, at 0.26-0.67 Gy/h, median 0.45 Gy/h.
RESULTS: The patients have been followed up for 32-158 months, median 50 months, and there were no recurrences. The applicator was well tolerated. A confluent mucositis developed which lasted 3-4 weeks. One patient developed a mucosal ulcer which healed spontaneously.
CONCLUSIONS: Brachytherapy is an effective way of delivering post-operative radiotherapy to the hard and soft palate in patients with malignant salivary gland tumours that have been incompletely excised or have unfavourable histology. Local control is excellent, treatment time is short and morbidity is minimal.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15588875     DOI: 10.1016/j.radonc.2004.09.001

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  A retrospective review of malignant minor salivary gland tumors and a proposed protocol for future care.

Authors:  Nickolaos Papadogeorgakis; Eleni Parara; Vasilis Petsinis; Eleni Pappa; Anastasios Nikolaidis; Konstantinos Alexandridis
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2011-03

2.  125I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region.

Authors:  M-W Huang; L Zheng; S-M Liu; Y Shi; J Zhang; G-Y Yu; J-G Zhang
Journal:  Strahlenther Onkol       Date:  2013-04-28       Impact factor: 3.621

3.  Postoperative [¹²⁵I] seed brachytherapy in the treatment of acinic cell carcinoma of the parotid gland: with associated risk factors.

Authors:  Ming-Hui Mao; Jian-Guo Zhang; Jie Zhang; Lei Zheng; Shu-Ming Liu; Ming-Wei Huang; Yan Shi
Journal:  Strahlenther Onkol       Date:  2014-04-29       Impact factor: 3.621

4.  A digital model individual template and CT-guided 125I seed implants for malignant tumors of the head and neck.

Authors:  Ming-Wei Huang; Shu-Ming Liu; Lei Zheng; Yan Shi; Jie Zhang; Yan-Sheng Li; Guang-Yan Yu; Jian-Guo Zhang
Journal:  J Radiat Res       Date:  2012-08-01       Impact factor: 2.724

5.  Three-dimensional verification of ¹²⁵I seed stability after permanent implantation in the parotid gland and periparotid region.

Authors:  Yi Fan; Ming-Wei Huang; Lei Zheng; Yi-Jiao Zhao; Jian-Guo Zhang
Journal:  Radiat Oncol       Date:  2015-11-24       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.